News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catabasis Pharmaceuticals, Inc. Describes Modulation Of SREBP As Mechanism For CAT-2003



5/1/2014 2:06:20 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals Inc. today announced the presentation of preclinical data demonstrating the mechanism of action for CAT-2003. The data were presented by Michael Zimmer, Ph.D., in an oral session at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions. The data demonstrate that CAT-2003 inhibits the transcription factor Sterol Regulatory Element Binding Protein (SREBP) in vitro and in vivo, resulting in the reduced expression of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), which normally acts to increase low-density lipoprotein (LDL) cholesterol. CAT-2003 currently is in a Phase 2 clinical trial for the treatment of patients with severe hypertriglyceridemias, including rare chylomicronemia syndromes.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES